Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01507584 · ClinicalTrials.gov registry record · NA

The Effects of the Water Drinking Test on Intraocular Pressure

A NA study of Glaucoma, sponsored by University of California, San Diego.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT01507584: Completed NA study of Glaucoma, sponsored by University of California, San Diego.

NCT01507584 is a NA study of Glaucoma that has completed, run by University of California, San Diego. The registered enrollment target is 23 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01507584, a NA study of Glaucoma, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This clinical trial is designed to investigate the efficacy profile of the SENSIMED Triggerfish® during 24-hour IOP monitoring in patients with glaucoma or ocular hypertension, done three times at monthly intervals under different therapeutic regimen. This trial will also evaluate the efficacy of SENSIMED Triggerfish® to detect changes in intraocular pressure (IOP) after the water drinking test (WDT) will be investigated.

Primary Outcome

Assess IOP patterns between day and night time and changes after the WDT.

Conditions Studied

Interventions

  • DEVICE SENSIMED Triggerfish

Study Locations (1)

California

  • Hamilton Glaucoma Center, UCSD - La Jolla

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2011-08
Est. Completion 2013-04-30
Phase NA
University of California, San Diego

775 total trials

What the finished NCT01507584 record still lists

NCT01507584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which SENSIMED Triggerfish is the first listed.

NCT01507584 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01507584 about?

NCT01507584 is a clinical study titled "The Effects of the Water Drinking Test on Intraocular Pressure". This clinical trial is designed to investigate the efficacy profile of the SENSIMED Triggerfish® during 24-hour IOP monitoring in patients with glaucoma or ocular hypertension, done three times at monthly intervals under different therapeutic regimen. This trial will also evaluate the efficacy of SE...

What is the current status of trial NCT01507584?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2011-08. Estimated completion is 2013-04-30.

What conditions does trial NCT01507584 study?

This clinical trial studies the following conditions: Glaucoma.

What interventions are being tested in trial NCT01507584?

The interventions under investigation include: SENSIMED Triggerfish (DEVICE).

Who is sponsoring clinical trial NCT01507584?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01507584 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01507584's enrollment target sits among peer trials

23 85th of 92 higher than 8 of 92 other Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01507584, the US trial registry maintained by the National Library of Medicine. NCT01507584 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.